859 related articles for article (PubMed ID: 11293643)
1. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
De Ponti F; Tonini M
Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
[TBL] [Abstract][Full Text] [Related]
2. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
Scarpignato C; Pelosini I
Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
[TBL] [Abstract][Full Text] [Related]
3. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
Farthing MJ
Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
[TBL] [Abstract][Full Text] [Related]
4. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
Moskwa A; Boznańska P
Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
[TBL] [Abstract][Full Text] [Related]
5. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
Tonini M; Pace F
Dig Dis; 2006; 24(1-2):59-69. PubMed ID: 16699264
[TBL] [Abstract][Full Text] [Related]
6. Drug therapy options for patients with irritable bowel syndrome.
Talley NJ
Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
[TBL] [Abstract][Full Text] [Related]
7. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications.
Talley NJ
Aliment Pharmacol Ther; 1992 Jun; 6(3):273-89. PubMed ID: 1600046
[TBL] [Abstract][Full Text] [Related]
8. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
Gershon MD
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
[TBL] [Abstract][Full Text] [Related]
9. Tegaserod and other serotonergic agents: what is the evidence?
Chey WD
Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
[TBL] [Abstract][Full Text] [Related]
10. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds.
Callahan MJ
J Clin Gastroenterol; 2002 Jul; 35(1 Suppl):S58-67. PubMed ID: 12184141
[TBL] [Abstract][Full Text] [Related]
11. Irritable bowel syndrome: update on pathogenesis and management.
Alaradi O; Barkin JS
Med Princ Pract; 2002; 11(1):2-17. PubMed ID: 12116690
[TBL] [Abstract][Full Text] [Related]
12. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.
Humphrey PP; Bountra C; Clayton N; Kozlowski K
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738
[TBL] [Abstract][Full Text] [Related]
13. Serotonergic modulation and irritable bowel syndrome.
Borman R
Expert Opin Emerg Drugs; 2001 Apr; 6(1):57-68. PubMed ID: 15989496
[TBL] [Abstract][Full Text] [Related]
14. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Lewis JH
Drug Saf; 2011 Jul; 34(7):545-65. PubMed ID: 21663331
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.
Binienda A; Storr M; Fichna J; Salaga M
Curr Drug Targets; 2018; 19(15):1774-1781. PubMed ID: 29284389
[TBL] [Abstract][Full Text] [Related]
16. The role of serotonin in the pathophysiology of irritable bowel syndrome.
Crowell MD
Am J Manag Care; 2001 Jul; 7(8 Suppl):S252-60. PubMed ID: 11474910
[TBL] [Abstract][Full Text] [Related]
17. Treatment goals in irritable bowel syndrome.
Kellow JE
Int J Clin Pract; 2001 Oct; 55(8):546-51. PubMed ID: 11695076
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle.
Prins NH; Van Haselen JF; Lefebvre RA; Briejer MR; Akkermans LM; Schuurkes JA
Br J Pharmacol; 1999 Jul; 127(6):1431-7. PubMed ID: 10455293
[TBL] [Abstract][Full Text] [Related]
19. Emerging treatments for irritable bowel syndrome.
Ahn J; Ehrenpreis ED
Expert Opin Pharmacother; 2002 Jan; 3(1):9-21. PubMed ID: 11772329
[TBL] [Abstract][Full Text] [Related]
20. [Recent insights into the pathogenesis of abdominal symptoms in functional bowel disorders].
Cervio E; Rondanelli M; Balestra B; Dellabianca A; Agazzi A; Giacosa A; Tonini M
Recenti Prog Med; 2007 Feb; 98(2):69-73. PubMed ID: 17439064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
